Figure 2. Proportion of Novel Therapeutics Approved by the US Food and Drug Administration (FDA) From 2001 Through 2010 Affected by Any Postmarket Safety Event as of February 2017.

The median time from approval to the first event was 4.2 years (interquartile range, 2.5-6.0 years).